Core Viewpoint - A class action has been initiated against Sana Biotechnology, Inc. for allegedly misleading investors regarding its financial stability and product development during the specified Class Period from March 17, 2023, to November 4, 2024 [1][3]. Group 1: Class Action Details - Investors who purchased securities during the Class Period can file a lead plaintiff motion by May 20, 2025 [1]. - The Portnoy Law Firm is offering complimentary case evaluations to affected investors [2]. Group 2: Allegations Against the Company - The complaint claims that Sana was at significant risk of lacking sufficient capital to sustain operations and product development [3]. - It is alleged that the Company's product programs, including SC291 in oncology, SC379, and SG299, were less promising than represented [3]. - The complaint suggests that Sana may reduce funding for or discontinue certain product candidates and significantly cut its workforce to conserve cash [3]. - As a result, the public statements made by the Company were materially false and misleading throughout the Class Period [3].

NEW YORK, April 15, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sana Biotechnology, Inc. (NASDAQ: SANA) between March 17, 2023 and November 4, 2024, inclusive (the "Class Period"), of the important May 20, 2025 lead plaintiff deadline. Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 case@rosenlegal.com www ...

Core Viewpoint - The article discusses the investigation into Sana Biotechnology, Inc. for potential securities law violations, highlighting significant financial risks and operational changes that have impacted the company's stock performance. Group 1: Legal Investigation - Faruqi & Faruqi, LLP is investigating potential claims against Sana Biotechnology, reminding investors of the May 20, 2025 deadline to seek lead plaintiff status in a federal securities class action [2] - The complaint alleges that Sana and its executives made false or misleading statements regarding the company's financial health and product development [4] Group 2: Financial Performance and Operational Changes - On October 10, 2023, Sana announced a reduction in near-term spending on its fusogen platform and a 29% headcount reduction, aiming to keep its 2024 operating cash burn below $200 million [5][6] - Following this announcement, Sana's stock price fell by $0.34 per share, or 8.95%, closing at $3.46 per share [6] - On November 4, 2024, Sana announced the suspension of development for SC291 and SC379, reallocating resources to its type 1 diabetes program, which extended its cash runway into 2026 [7] - This announcement led to a further decline in stock price by $0.37 per share, or 9.84%, closing at $3.39 per share [7]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Sana Biotechnology, Inc. during the specified Class Period of the upcoming lead plaintiff deadline on May 20, 2025, for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who purchased Sana securities between March 17, 2023, and November 4, 2024, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by May 20, 2025 [2]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [3]. - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [3]. Group 3: Case Allegations - The lawsuit alleges that during the Class Period, Sana made false and misleading statements regarding its financial stability and the potential of its product candidates, including SC291, SC379, and SG299 [4]. - It is claimed that Sana was at significant risk of insufficient funds to maintain operations and that the company was likely to decrease funding for certain product candidates and reduce its workforce [4].

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Sana To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Sana between March 17, 2023 and November 4, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, April 09, 2025 (GLOBE NEWSWIRE) -- Faruqi & Far ...

NEW YORK, April 8, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Sana Biotechnology, Inc. ("Sana Biotechnology, Inc." or the "Company") (NASDAQ: SANA) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Sana Biotechnology, Inc. investors who were adversely affected by alleged securities fraud between March 17, 2023 and November 4, 2024. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com ...

Core Viewpoint - A class action lawsuit has been filed against Sana Biotechnology, Inc. for allegedly misleading investors regarding its financial stability and product development capabilities [1][2]. Group 1: Allegations and Financial Concerns - The lawsuit claims that Sana was at significant risk of having insufficient funds to maintain operations and advance its product candidates [2]. - Specific product candidates, including SC291 in oncology, SC379, and SG299, were reportedly less promising than what the company had communicated to investors [2]. - To conserve cash and focus on more promising candidates, Sana was likely to reduce funding for or discontinue certain projects and significantly cut its workforce [2]. - The defendants are accused of overstating Sana's financial capacity to sustain operations and advance existing product candidates [2]. Group 2: Class Action Participation - Shareholders interested in serving as lead plaintiffs must file their papers with the court by May 20, 2025 [3]. - Participation in the case is not required to be eligible for recovery; shareholders can remain absent class members if they choose [3]. Group 3: Company Background - Robbins LLP is noted as a leader in shareholder rights litigation, focusing on helping shareholders recover losses and improve corporate governance since 2002 [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Sana Biotechnology, Inc. due to allegations of misleading statements regarding the company's financial health and product development, with a deadline for investors to seek lead plaintiff status in a class action lawsuit by May 20, 2025 [2][4]. Group 1: Allegations Against Sana - The complaint alleges that Sana and its executives violated federal securities laws by making false or misleading statements about the company's financial stability and product candidates [4]. - Specific claims include that Sana was at significant risk of insufficient funds to maintain operations and that certain product candidates were less promising than previously stated [4]. - The company is accused of overstating its financial capacity and failing to disclose plans to reduce funding for certain projects and decrease its workforce [4]. Group 2: Recent Developments - On October 10, 2023, Sana announced a reduction in spending on its fusogen platform and a 29% headcount reduction, aiming to keep its 2024 operating cash burn below $200 million [5][6]. - Following this announcement, Sana's stock price fell by $0.34 per share, or 8.95%, closing at $3.46 per share [6]. - On November 4, 2024, Sana suspended development of two product candidates and shifted focus to its type 1 diabetes program, which led to a further stock price decline of $0.37 per share, or 9.84%, closing at $3.39 per share [7].

NEW YORK, April 4, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Sana Biotechnology, Inc. ("Sana Biotechnology, Inc." or the "Company") (NASDAQ: SANA) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Sana Biotechnology, Inc. investors who were adversely affected by alleged securities fraud between March 17, 2023 and November 4, 2024. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com ...

NEW YORK, April 03, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Sana Biotechnology, Inc. (NASDAQ: SANA). Shareholders who purchased shares of SANA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/sana-biotechnology-inc-loss-submission-form/?id=140415&from=3  CLASS PER ...